Search Results

PRISM BioLab, Co. Ltd. announced that it has entered into a target-exclusive research and licensing agreement with ONO PHARMACEUTICAL CO., LTD.

ClearPoint Neuro, Inc. today announced it has received 510(k) clearance for its Prism Bone Anchor Accessory.

PRISM MarketView, a leader within the financial markets and news community, announces the release of an article highlighting Soligenix Inc’s (Nasdaq: SNGX) key achievements and pathway to regulatory success through its lead product candidate, HyBryte™ (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma, a rare and chronic cancer.

ClearPoint Neuro, Inc. announces full market release of its SmartFrame OR platform and ClearPoint Prism Neuro Laser Therapy System at the 2024 Biennial Meeting of the American Society of Stereotactic and Functional Neurosurgery from Saturday, June 1st – Tuesday, June 4th in Nashville.

4D Molecular Therapeutics today announced that the Company will present the initial interim 24-week landmark analysis from the Population Extension cohort of the PRISM Phase 2 Clinical Trial evaluating 4D-150 in a broad wet AMD patient population at the ASRS Annual Scientific Meeting being held in Stockholm, Sweden from July 17-20, 2024.

PRISM BioLab, Co. Ltd. (“PRISM”), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a License and Collaboration Agreement with Eli Lilly and Company (“Lilly”).

4D Molecular Therapeutics presented supplemental aflibercept injection-free subgroup analyses of the previously reported 24-week landmark results from the randomized Dose Expansion cohort from the Phase 2 PRISM clinical trial evaluating intravitreal 4D-150 in wet age-related macular degeneration patients with severe disease activity and a high treatment burden.

PRISM BioLab, Co. Ltd., a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction targets, announced a 1.5 billion yen fundraise.